Pharmaceutical industry news

Top Biotech Picks From Needham & Company for Second Half of 2026

Gregg Gorniak on Turning DSCSA Compliance Into Strategic Opportunity

Could This New Opportunity Be Worth Billions for Novo Nordisk?

Sartorius Stedim stock gains support as Q2 margins hold and analysts stay positive

Freedom Broker expects a correction in the U.S. biotech sector

System secures US$20 million as peptide wellness market accelerates.

Mapping the Global Health Landscape: Analysis of Fourteen International Organizations

Scancell’s Phase 3 Melanoma Vaccine Trial Moves Toward Launch, Raising Long-Term Upside Questions

Why Patients With the Same Cancer Respond Differently to Treatment

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Amgen Drops 10% on a Trial It Didn't Even Run

Psychedelics are on the FDA’s mind

FDA extends review of Exelixis’ colorectal cancer drug candidate

Get ready to experience iPhone 18 Pro, the new Apple Watch lineup, and AirPods 5

Obispos de Chile invitan a mirar el futuro desde la unidad y la amistad cívica

Maharashtra FDA Suspends 199 Eatery Licences Over Hygiene

Clarity on AI responsibilities in healthcare needed, National Commission says

PharmTech Weekly Roundup—September 11, 2026

New FDA Drug Approvals - August 2026

Pancreatic cancer drug may also help fight treatment-resistant lung cancer

Gregg Gorniak: What Changed in Five Years of DSCSA?

Simultaneous anaerobic bioreactor could accelerate sustainable biomanufacturing

FDA Grants Final Approval to Cabozantinib Capsules Across Multiple Solid Tumor Indications

Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial

Duopharma Biotech Detects Unauthorised System Access Attempt

The 2026 state of FSP outsourcing: challenges, trends, opportunities and the future of clinical development

FDA Grants Orphan Drug Status to Lundbeck's Asedebart for Cushing

Study shows early treatment can prevent long-term complications in Crohn’s disease

News by CNBC TV18 on TradingView, 2026-09-11 — cnbctv:df10e080b094b:0

Sex ratios at birth in the UK: 2018 to 2022

Analysis of male to female birth ratios in the UK for the period 1 January 2018 to 31 December 2022.

Deep Learning System Detects Lesions in Sacroiliac Joints

PTC Therapeutics at cantor healthcare conference: sephience drives growth By Investing.com

Can Vaginal Estrogen Cream Erase Signs of Aging on Your Face?

NHSR, Exempt, Expedited, or Full Board? A Plain-Language Guide to Potential Review Pathways

FDA Expands Hyrnuo Use in HER2-Mutated Lung Cancer

Université Paris Cité at EAIE 2026 in Glasgow

Why Pharma's Next AI Challenge Is Supervision, Not Adoption

US FDA extends review of Exelixis’ cancer drug

WATCH: Conversations on America's global biotech leadership

How the mosquito’s carbon dioxide sense gets an internal boost

Novartis drags peers down with triple asset stumble

FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer

The future of RAS inhibitors

How Pharmaceutical Logistics Comes Together

5 things to know in life sciences: Week of Sept. 7, 2026

FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027

USFDA Imposes Partial Clinical Hold on Biohaven's Epilepsy Drug Over Rodent Findings

Pneumococcal disease: cases caused by serotypes not covered by PCV13

Cumulative weekly data on invasive pneumococcal disease (IPD) infections due to serotypes not in Pre...

Pneumococcal disease: cases caused by serotypes covered by PCV13

Cumulative weekly data on invasive pneumococcal disease (IPD) infections due to serotypes in Prevena...

Cancer drug shortages keep disrupting patient care

Eli Lilly completes acquisition of AtaiBeckley, initiates delisting from Nasdaq

Novo Holdings and leading international funds are investing nearly DKK 60m in a new Danish biotech company

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks

Dr. J.P. McAleer – Lapiplasty®S4A

US FDA extends review of Exelixis' cancer drug

Beyond Simple Allometric Scaling: Why Time-Course Methods Win for First-in-Human Predictions

ERS 2026: BMI, type-2 inflammation, and asthma attack risk

New light-emitting nanoparticles can detect subtle chemical differences to enhance pharmaceutical manufacturing, pollution prevention and more

Lundbeck drug candidate granted another US FDA designation

AbbVie’s Atogepant delivers positive Phase 3 results in menstrual migraine